Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.

Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Hartmann B, Holst JJ, Vilsbøll T, Andersen HU, Knop FK

Diabetes, obesity & metabolism18 Oct 2021Cited by 18 (Europe PMC)

PMID34617375DOI10.1111/dom.14568PepBankPUB-34617375

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide reduced body weight by 4.4 kg versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide reduced body weight by 4.4 kg versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 108
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight reduction
4.4 kg
exenatide versus placebo
Source sentences
Summary
Exenatide elicited a body weight reduction of 4.4 kg compared with placebo,
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, whole-body bone density did not differ between exenatide and placebo.
In plain wordsIn adults with type 1 diabetes, whole-body bone density did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWhole-body bone mineral density
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between-group differences in bone mineral density, as assessed by whole-body, hip, lumbar, and forearm dual-energy X-ray absorptiometry following 26 weeks of treatment, were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, hip bone density did not differ between exenatide and placebo.
In plain wordsIn adults with type 1 diabetes, hip bone density did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHip bone mineral density
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between-group differences in bone mineral density, as assessed by whole-body, hip, lumbar, and forearm dual-energy X-ray absorptiometry following 26 weeks of treatment, were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, lumbar bone density did not differ between exenatide and placebo.
In plain wordsIn adults with type 1 diabetes, lumbar bone density did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLumbar bone mineral density
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between-group differences in bone mineral density, as assessed by whole-body, hip, lumbar, and forearm dual-energy X-ray absorptiometry following 26 weeks of treatment, were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737504
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, forearm bone density did not differ between exenatide and placebo.
In plain wordsIn adults with type 1 diabetes, forearm bone density did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeForearm bone mineral density
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between-group differences in bone mineral density, as assessed by whole-body, hip, lumbar, and forearm dual-energy X-ray absorptiometry following 26 weeks of treatment, were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737505
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change fasting collagen telopeptides versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide did not change fasting collagen telopeptides versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeC-terminal telopeptides of type I collagen
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737506
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, exenatide did not change fasting procollagen propeptide versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide did not change fasting procollagen propeptide versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAmino-terminal propeptide of type I procollagen
Study
n = 108
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 μg before breakfast, lunch, and dinner · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Fasting plasma levels of C-terminal telopeptides of type I collagen, a marker of bone resorption, and amino-terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In a randomized, double-blinded, parallel-group trial,
Summary · context
were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add-on treatment to insulin therapy.
Report a problemFND-3461737507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.